Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AAV2sFLT 01 - Beacon Therapeutics

Drug Profile

AAV2sFLT 01 - Beacon Therapeutics

Alternative Names: AAV2-sFLT01; age-related macular degeneration gene therapy - Beacon Therapeutics; anti vascular endothelial growth factor (VEGF) gene therapy - Beacon Therapeutics; GZ-402663; sFLT-01

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Applied Genetic Technologies Corporation; Genzyme Corporation
  • Developer Beacon Therapeutics; JDRF; Sanofi
  • Class Eye disorder therapies; Gene therapies
  • Mechanism of Action Gene transference; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Age-related macular degeneration
  • Discontinued Diabetic retinopathy

Most Recent Events

  • 28 Sep 2020 No recent reports of development identified for phase-I development in Age-related-macular-degeneration in USA (Intravitreous, Injection)
  • 01 Jul 2018 Phase I development in Age-related macular degeneration is ongoing in USA (Intravitreous) (NCT01024998)
  • 01 Jul 2018 Genzyme completes a phase I trial in Age-related macular degeneration in USA (Intravitreous) (NCT01024998)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top